Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
123 hedge funds and large institutions have $693M invested in Aerie Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 46 increasing their positions, 27 reducing their positions, and 9 closing their positions.
530% more call options, than puts
Call options by funds: $8.1M | Put options by funds: $1.28M
300% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 9
70% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 27
26% more funds holding
Funds holding: 98 → 123 (+25)
8% more capital invested
Capital invested by funds: $641M → $693M (+$52.4M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$20.7M |
| 2 |
Jennison Associates
New York
|
+$17.7M |
| 3 |
Millennium Management
New York
|
+$12.3M |
| 4 |
HM
HealthCor Management
New York
|
+$10.1M |
| 5 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
+$9.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CV
Clarus Ventures
Cambridge,
Massachusetts
|
-$97.4M |
| 2 |
DM
Deerfield Management
New York
|
-$36.3M |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
-$9.3M |
| 4 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
-$7.25M |
| 5 |
MSA
Mason Street Advisors
Milwaukee,
Wisconsin
|
-$3.04M |
AERI Hedge Fund Activity: Q1 2015 in Review
123 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q1 2015, worth a combined $693M — up 8.2% from $641M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new AERI positions and 9 closed out — a net gain of 27 holders — while 46 added to existing stakes and 27 trimmed.
The largest buyer was State Street, adding an estimated $20.7M. The largest seller was Clarus Ventures, exiting entirely with an estimated $97.4M sold.
- 123 institutional investors held Aerie Pharmaceuticals (AERI) as of Q1 2015, up from 98 in Q4 2014.
- Funds reported $693M of Aerie Pharmaceuticals stock for Q1 2015, up 8.2% quarter-over-quarter.
- 36 funds opened new Aerie Pharmaceuticals positions in Q1 2015 and 9 closed out, a net change of +27 holders.
- The largest Aerie Pharmaceuticals buyer in Q1 2015 was State Street, an estimated $20.7M added.
- The largest Aerie Pharmaceuticals seller in Q1 2015 was Clarus Ventures, an estimated $97.4M sold.
Based on aggregated 13F filings for Q1 2015.